AbbVie reported stronger-than-expected third-quarter results, driven by robust performance in its immunology and neuroscience divisions. The pharmaceutical company raised its full-year profit outlook and increased its quarterly dividend, reflecting confidence in its portfolio and growth trajectory. Both revenue and earnings per share exceeded analyst estimates, with key products such as Humira and Skyrizi continuing to deliver strong sales.
The company also highlighted progress in its neuroscience segment, particularly with drugs like Vraylar and Ubrelvy. AbbVie's updated guidance signals sustained momentum, supported by ongoing demand for its specialty treatments and a diversified product mix. Executives emphasized the importance of innovation and commercial execution in maintaining growth amid a competitive landscape.
Source: Wall Street Journal US Business · Summarized by HeadlinesBriefing